title: [Influence of aluminum adjuvant to experimental rabies vaccine].
abstract: OBJECTIVE
  To study whether the rabies vaccine for human use should contain aluminum adjuvant.
  
  
  METHODS
  Testing vaccine antibodies and efficacy (ED50), comparing the effect between aluminum adjuvant contained and non-aluminum adjuvant contained vaccines in a new animal model which accords with the rabies field practice.
  
  
  RESULTS
  At fourth and seventh day after immunization, the neutralizing antibody titres of the rabies vaccine containing aluminium adjuvant were much lower than that of the vaccine not containing aluminum adjuvant. In the NIH efficacy test the ED50 of the vaccine containing aluminum adjuvant was 93-132 ng while the ED50 of the vaccine not containing aluminum adjuvant was 221 ng, but the NIH test does not accord with the rabies field practice. In that new animal model, aluminum adjuvant to rabies vaccine had not any promoting effect for preventing and treating rabies.
  
  
  CONCLUSIONS
  Aluminum adjuvant to rabies vaccine has no advantages, this paper suggests that the vaccines containing and not-containing aluminium adjuvant had better compare in human bodies. If the results are the same as our experiments, the aluminum adjuvant should be eliminated from rabies vaccine for human use.
authors.affiliation: National Institute for the Control of Pharmaceutical and Biololgical Products, Beijing 100050.
authors.forename: H
authors.initials: H
authors.lastname: Lin
authors.forename: P
authors.initials: P
authors.lastname: Perrin
mesh_terms: D000277:Adjuvants, Pharmaceutic / Q000009:adverse effects*; D000535:Aluminum / Q000009:adverse effects*; D000818:Animals; D000914:Antibodies, Viral / Q000096:biosynthesis*; D006801:Humans; D051379:Mice; D011819:Rabies Vaccines / Q000276:immunology*
chemical_list: D000277:Adjuvants, Pharmaceutic; D000914:Antibodies, Viral; D011819:Rabies Vaccines; D000535:Aluminum